Alto Neuroscience Appoints New Chief Medical Officer
Ticker: ANRO · Form: 8-K · Filed: May 21, 2024 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $470,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
Alto Neuroscience just hired a new CMO from Genentech to lead their drug development. Big move for their pipeline.
AI Summary
Alto Neuroscience, Inc. announced on May 21, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller, previously a Senior Medical Director at Genentech, brings extensive experience in neuroscience drug development. This appointment is part of Alto's ongoing efforts to advance its pipeline of novel therapies for neurological and psychiatric disorders.
Why It Matters
The appointment of a new Chief Medical Officer with significant industry experience could signal a strategic shift or acceleration in Alto Neuroscience's drug development programs, potentially impacting the company's future clinical trial progress and regulatory submissions.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a CMO is significant, but the filing itself does not contain information about the company's financial health or market performance, necessitating a medium risk assessment.
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- Dr. Jonathan F. Miller (person) — Appointed Chief Medical Officer
- Genentech (company) — Dr. Miller's former employer
- May 21, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer at Alto Neuroscience?
Dr. Jonathan F. Miller has been appointed as the new Chief Medical Officer.
What was Dr. Jonathan F. Miller's previous role?
Dr. Miller was previously a Senior Medical Director at Genentech.
When was this appointment announced?
The appointment was announced on May 21, 2024.
What is Alto Neuroscience's primary business focus?
Alto Neuroscience focuses on developing novel therapies for neurological and psychiatric disorders.
What is the company's state of incorporation?
Alto Neuroscience, Inc. is incorporated in Delaware.
Filing Stats: 1,206 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-05-21 08:29:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ANRO New York S
- $470,000 — nley will receive an annually salary of $470,000, which is subject to adjustment at the
Filing Documents
- d773656d8k.htm (8-K) — 28KB
- 0001193125-24-143369.txt ( ) — 149KB
- anro-20240521.xsd (EX-101.SCH) — 3KB
- anro-20240521_lab.xml (EX-101.LAB) — 18KB
- anro-20240521_pre.xml (EX-101.PRE) — 11KB
- d773656d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: May 21, 2024 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer